EP2742154A4 - Biomarker compositions and methods - Google Patents

Biomarker compositions and methods

Info

Publication number
EP2742154A4
EP2742154A4 EP12821745.2A EP12821745A EP2742154A4 EP 2742154 A4 EP2742154 A4 EP 2742154A4 EP 12821745 A EP12821745 A EP 12821745A EP 2742154 A4 EP2742154 A4 EP 2742154A4
Authority
EP
European Patent Office
Prior art keywords
methods
biomarker compositions
biomarker
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12821745.2A
Other languages
German (de)
French (fr)
Other versions
EP2742154A2 (en
Inventor
Kirk Brown
Traci Pawlowski
David Spetzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caris Life Sciences Switzerland Holdings GmbH
Original Assignee
Caris Life Sciences Switzerland Holdings GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caris Life Sciences Switzerland Holdings GmbH filed Critical Caris Life Sciences Switzerland Holdings GmbH
Publication of EP2742154A2 publication Critical patent/EP2742154A2/en
Publication of EP2742154A4 publication Critical patent/EP2742154A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
EP12821745.2A 2011-08-08 2012-08-08 Biomarker compositions and methods Withdrawn EP2742154A4 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201161521333P 2011-08-08 2011-08-08
US201161523763P 2011-08-15 2011-08-15
US201161526623P 2011-08-23 2011-08-23
US201161529762P 2011-08-31 2011-08-31
US201161534352P 2011-09-13 2011-09-13
US201161537462P 2011-09-21 2011-09-21
US201161542639P 2011-10-03 2011-10-03
US201161551674P 2011-10-26 2011-10-26
US201161559676P 2011-11-14 2011-11-14
US201261612111P 2012-03-16 2012-03-16
US201261619803P 2012-04-03 2012-04-03
PCT/US2012/050030 WO2013022995A2 (en) 2011-08-08 2012-08-08 Biomarker compositions and methods

Publications (2)

Publication Number Publication Date
EP2742154A2 EP2742154A2 (en) 2014-06-18
EP2742154A4 true EP2742154A4 (en) 2015-08-12

Family

ID=47669214

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12821745.2A Withdrawn EP2742154A4 (en) 2011-08-08 2012-08-08 Biomarker compositions and methods

Country Status (8)

Country Link
EP (1) EP2742154A4 (en)
JP (1) JP2014522993A (en)
KR (1) KR20140067001A (en)
CN (1) CN103874770A (en)
AU (1) AU2012294458A1 (en)
BR (1) BR112014002975A2 (en)
CA (1) CA2844671A1 (en)
WO (1) WO2013022995A2 (en)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009246180B2 (en) 2008-05-14 2015-11-05 Dermtech International Diagnosis of melanoma and solar lentigo by nucleic acid analysis
JP5808349B2 (en) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー Biomarkers for theranosis
KR20130043104A (en) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 Circulating biomarkers for disease
CA2877721A1 (en) 2012-06-27 2014-01-03 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
CN103160509B (en) * 2013-03-07 2015-02-18 新乡医学院第一附属医院 miRNA marker relative to esophagus cancer postoperative early relapse and prognosis and application
EP2971162B1 (en) 2013-03-15 2019-05-08 Board Of Regents, The University Of Texas System Mirna biogenesis in exosomes for diagnosis and therapy
CN104076151B (en) * 2013-03-29 2017-04-12 复旦大学附属华山医院 Kit for early diagnosis of glioma
WO2014177576A1 (en) * 2013-04-29 2014-11-06 Apogenix Gmbh Method of diagnosing cancer
EP2994545B1 (en) 2013-05-10 2019-03-20 University Of Southern California Dna methylation biomarkers for bladder cancer
JP2016526922A (en) * 2013-08-06 2016-09-08 エクソサム ダイアグノスティクス，インコーポレイティド Urine biomarker cohort, gene expression characteristics, and methods of use thereof
CN105659085B (en) * 2013-08-28 2018-12-07 中美冠科生物技术（太仓）有限公司 Predict subject to the gene expression mark and its application method of the reaction of multi-kinase inhibitor
AU2014312211A1 (en) * 2013-08-28 2016-03-10 Caris Science, Inc. Oligonucleotide probes and uses thereof
WO2015068772A1 (en) * 2013-11-06 2015-05-14 Jsr株式会社 Separation method, detection method, signal measurement method, method for determining disease, method for evaluating drug efficacy of disease treatment drug, kit, and liquid composition
FR3014198B1 (en) * 2013-12-03 2017-03-03 Biomerieux Sa METHOD FOR ISOLATING EXOSOMES
WO2015083829A1 (en) * 2013-12-06 2015-06-11 国立大学法人東京大学 Valve, fluid-controlling structure, fluid device, and method for manufacturing valve
JP2017509351A (en) * 2013-12-30 2017-04-06 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Prostate cancer gene profile and method of use thereof
EP3090064B1 (en) 2013-12-31 2019-11-13 Yeda Research and Development Co. Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
WO2015117164A1 (en) * 2014-02-03 2015-08-06 Memorial Sloan-Kettering Cancer Center Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders
WO2015165973A1 (en) 2014-04-29 2015-11-05 Apogenix Gmbh Diagnostic anti-cd95l antibody
JP2017514519A (en) * 2014-05-01 2017-06-08 スティヒティング フェーユーエムセー Small non-coding RNA as a biomarker
US10619213B2 (en) 2014-06-12 2020-04-14 Toray Industries, Inc. Prostate cancer detection kit or device, and detection method
ES2481819B1 (en) * 2014-06-12 2015-04-01 Sistemas Genómicos, S.L. ASSESSMENT METHOD TO EVALUATE A POSSIBILITY OF BREAST CANCER
US20160038608A1 (en) * 2014-08-07 2016-02-11 National Taiwan University Silica-based mesoporous carrier and delivery method of using the same
US10670611B2 (en) * 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
KR101596166B1 (en) 2014-10-07 2016-02-19 가톨릭대학교 산학협력단 A Use of microRNA for Ddiagnosing and Treating Brest Cancer
CN104313171A (en) * 2014-11-06 2015-01-28 南京大学 MicroRNA molecular marker for diagnosing glioma and application of microRNA molecular marker
EP4242329A3 (en) 2014-12-08 2023-10-25 Berg LLC Use of markers including filamin a in the diagnosis and treatment of prostate cancer
CN105807063B (en) * 2014-12-29 2018-02-06 中国人民解放军第二军医大学 Applications of the CD63 in preparing diagnosis for liver disease kit or preparing prevention or treatment liver diseases medicine
CN104548134A (en) * 2015-01-04 2015-04-29 中国人民解放军第二军医大学 Application of miR-144 and inhibitor thereof
WO2016112031A1 (en) * 2015-01-05 2016-07-14 The Johns Hopkins University Method of epigenetic analysis for determining clinical genetic risk
WO2016121821A1 (en) * 2015-01-27 2016-08-04 Jsr株式会社 Separation method, detection method, signal measurement method, method for determining disease, method for evaluating drug efficacy, kit, liquid composition, and analyte diluent
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL284985B2 (en) 2015-02-18 2023-03-01 Enlivex Therapeutics R& D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN107533058A (en) 2015-03-01 2018-01-02 免疫阵列有限公司 Use albumen, peptide and oligonucleotides diagnostic antigen systemic loupus erythematosus
AU2016229076B2 (en) 2015-03-09 2022-01-20 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN104714032B (en) * 2015-04-02 2015-09-16 闫星宇 For mark and the detection reagent thereof of postpartum eclampsia diagnosis
CA2982452A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
EP3299816A4 (en) * 2015-05-20 2018-10-03 JSR Corporation Separation method, detection method, signal measurement method, disease determination method, drug efficacy assessment method, kit, liquid composition, and specimen diluent
EP3307890A1 (en) 2015-06-10 2018-04-18 Board of Regents, The University of Texas System Use of exosomes for the treatment of disease
CN104992058B (en) * 2015-06-25 2017-08-01 成都厚立信息技术有限公司 Disease risks adjust method for establishing model
CA2991045A1 (en) 2015-06-29 2017-01-05 Caris Science, Inc. Therapeutic oligonucleotides binding c1q
CN105177117A (en) * 2015-07-03 2015-12-23 张理义 Major depressive disorder biomarker, screening method and kit
CN106350578A (en) * 2015-07-13 2017-01-25 中国人民解放军第二军医大学 Application of NY-ESO-1 in diagnosis and treatment of microsatellite instability intestinal cancer
US10941176B2 (en) 2015-07-28 2021-03-09 Caris Science, Inc. Therapeutic oligonucleotides
CN105039342B (en) * 2015-08-06 2017-12-01 李家平 SiRNA and its application of MAT2A gene expressions can be suppressed
WO2017025954A1 (en) * 2015-08-09 2017-02-16 Immunarray Ltd Methods for determining the risk of a systemic lupus erythematosus (sle) patient to develop neuropsychiatric syndromes
CN105067822B (en) * 2015-08-12 2017-05-24 中山大学附属肿瘤医院 Marker for diagnosing esophagus cancer
JP6583817B2 (en) * 2015-09-04 2019-10-02 国立大学法人山口大学 Diagnostic markers for tumors in uterine smooth muscle
KR102087373B1 (en) * 2015-09-11 2020-03-10 주식회사 압타머사이언스 Protein biomarker panel for detecting non-small cell lung cancer and method for diagnosing a non-small cell lung cancer by the use thereof
BR112018005175A2 (en) 2015-09-17 2018-10-16 Amgen Inc prediction of clinical response to il23 antagonists using il23 pathway biomarkers
EP3165926A1 (en) * 2015-11-06 2017-05-10 Humanitas Mirasole S.p.A. Method for characterization of cell specific microvesicles
WO2017112921A1 (en) * 2015-12-24 2017-06-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for characterizing sepsis
WO2017113565A1 (en) * 2015-12-29 2017-07-06 中国医学科学院肿瘤医院 Kit for auxiliary diagnosis of patient with liver cancer or digestive tract cancer based on protein marker psg3
EP3416661A4 (en) 2016-02-18 2020-03-04 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
CA3018066A1 (en) 2016-03-18 2017-09-21 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN105842461A (en) * 2016-04-30 2016-08-10 广州恒泰生物科技有限公司 Rapid diagnostic kit for uterine sarcoma in early and middle stages and preparation method of kit
AU2017271579B2 (en) 2016-05-25 2023-10-19 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN107475356A (en) * 2016-06-08 2017-12-15 益善生物技术股份有限公司 Osteosarcoma circulating tumor cell identification kit
CN105907875A (en) * 2016-06-13 2016-08-31 武汉泰安康生物科技有限公司 Method for screening kidney cancer peripheral blood miRNA marker and kidney cancer marker miR-378
JP6980219B2 (en) * 2016-08-22 2021-12-15 いであ株式会社 How to detect cancer or determine the stage of cancer staging
EP3541958A1 (en) * 2016-11-15 2019-09-25 Ventana Medical Systems, Inc. Compositions and methods for prognosing and treating colorectal cancer
CN108165635B (en) * 2016-12-07 2021-07-13 南京农业大学 KIAA1462 gene promoter region variant site and application thereof in improving egg laying performance of geese
US20210072255A1 (en) 2016-12-16 2021-03-11 The Brigham And Women's Hospital, Inc. System and method for protein corona sensor array for early detection of diseases
CN114441747B (en) * 2016-12-16 2023-06-23 布里格姆及妇女医院股份有限公司 System and method for protein crown sensor array for early detection of disease
CN106636296A (en) * 2016-12-22 2017-05-10 广州医科大学附属肿瘤医院 Application of Hsp27 in tolerance diagnosis and treatment for tongue cancer chemotherapy
CN106501517B (en) * 2016-12-27 2018-05-08 北京蛋白质组研究中心 Detect application of the material of SPARC protein in serum in examination hepatocellular carcinoma kit is prepared
CN106939340A (en) * 2017-03-31 2017-07-11 哈尔滨医科大学 A kind of molecular marked compound related to adenocarcinoma of lung transfer and prognosis and its application
CN106947820B (en) * 2017-04-11 2020-09-29 成都望路医药技术有限公司 Application of VCAN in diagnosis and treatment of colon adenocarcinoma
CA3062858A1 (en) 2017-05-12 2018-11-15 The Regents Of The University Of Michigan Individual and cohort pharmacological phenotype prediction platform
CN106987649A (en) * 2017-05-31 2017-07-28 上海博慷生物科技有限公司 A kind of primer sets and detection method for being used to detect glioma
CN109085355A (en) * 2017-06-13 2018-12-25 中国医学科学院肿瘤医院 Serum protein markers combine the application in screening lung cancer and diagnosis and treatment
CN107273718A (en) * 2017-06-27 2017-10-20 电子科技大学 A kind of Analysis of Survival Time method of fusion dna methylation characteristic
JP7029719B2 (en) * 2017-08-31 2022-03-04 静岡県 Biomarker
CN107630092B (en) * 2017-10-23 2020-03-31 广州医科大学附属第二医院 Application of miR-505-3p in diagnosis, prognosis and treatment of bone metastasis of prostate cancer
CN111512158B (en) * 2017-12-22 2023-12-12 威斯康星校友研究基金会 Nanoengineered surfaces for cancer biomarker capture
CN107868829B (en) * 2017-12-26 2021-05-18 浙江自贸区锐赛生物医药科技有限公司 Combined reagent and kit for evaluating postoperative recurrence risk of chordoma and application of combined reagent and kit
CN107937621A (en) * 2018-01-12 2018-04-20 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） The application of miRNA, product and detection method using it
CN108192970A (en) * 2018-01-24 2018-06-22 苏州大学 A kind of diagnosing cancer of liver marker and its application
CN108048460B (en) * 2018-02-01 2021-04-09 浙江大学 Novel molecular marker and application thereof in preparation of kit for head and neck cancer diagnosis and prognosis
KR20200143462A (en) 2018-04-13 2020-12-23 프리놈 홀딩스, 인크. Implementing machine learning for testing multiple analytes in biological samples
FR3080185A1 (en) * 2018-04-16 2019-10-18 Biomerieux EVALUATION OF THE RISK OF COMPLICATION IN A PATIENT SUSPECTED TO HAVE AN INFECTION HAVING A SOFA SCORE LESS THAN TWO
CN108570501B (en) * 2018-04-28 2020-06-12 北京师范大学 Multiple myeloma molecular typing and application
CN108559778B (en) * 2018-04-28 2020-06-12 北京师范大学 Multiple myeloma molecular typing and application thereof in medication guidance
CN108586579B (en) * 2018-05-11 2021-11-30 京东方科技集团股份有限公司 Quasi-peptide, derivative, salt, preparation method and application thereof
CN113855675A (en) * 2018-05-22 2021-12-31 郑州大学第一附属医院 Kit and medicine based on gallbladder cancer marker
CN108841962B (en) * 2018-08-01 2021-11-19 博奥生物集团有限公司 Non-small cell lung cancer detection kit and application thereof
KR102094608B1 (en) * 2018-08-08 2020-04-23 고려대학교 산학협력단 Method for Providing Information on Classification and Prognosis of Hematologic Malignancy
US11535899B2 (en) 2018-08-10 2022-12-27 Toray Industries, Inc. Kit, device and method for detecting prostate cancer
CN109321656B (en) * 2018-10-22 2021-10-01 上海交通大学医学院附属仁济医院 Use of protein DEPDC1 as marker for diagnosing triple-negative breast cancer
CN112955551A (en) * 2018-11-01 2021-06-11 花王株式会社 Method for producing nucleic acid derived from skin cell of subject
CA3118666A1 (en) 2018-11-07 2020-05-14 Seer, Inc. Compositions, methods and systems for protein corona analysis and uses thereof
CN109507425A (en) * 2018-11-07 2019-03-22 国家纳米科学中心 Carcinoma of prostate based on the extracellular vesica of thermophoresis recurs monitoring system and method
WO2020104588A1 (en) * 2018-11-22 2020-05-28 Institut D'investigació Sanitària Pere Virgili Biomarkers of prostate cancer aggressiveness
CN109609630B (en) * 2018-12-03 2023-01-13 哈尔滨医科大学 Molecular marker for early gastric cancer diagnosis and application thereof
CN109439757A (en) * 2018-12-18 2019-03-08 首都医科大学附属北京佑安医院 Application of the blood plasma excretion body miR-455-3p as early liver cancer diagnosis marker
CN109652504B (en) * 2018-12-27 2021-03-16 杭州迪相实业有限公司 Method for simultaneously detecting exosome membrane protein and mRNA
US20220088016A1 (en) * 2019-01-02 2022-03-24 Zhejiang Crownmab Biotech Co. Ltd. Cancer treatment using multi-targeted kinase inhibitor in combination of protein kinase biomarkers
CN109609653B (en) * 2019-02-12 2019-07-19 山东大学齐鲁医院 The molecular marked compound and its application of diagnosis or treatment glioma
EP3699300A1 (en) * 2019-02-22 2020-08-26 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Seminal mirnas as non-invasive biomarkers for the diagnosis and/or prognosis of prostate cancer
US11578373B2 (en) 2019-03-26 2023-02-14 Dermtech, Inc. Gene classifiers and uses thereof in skin cancers
CN110196329A (en) * 2019-05-31 2019-09-03 郑州大学第一附属医院 A kind of cancer of the esophagus early stage combined detection kit
JPWO2020262374A1 (en) * 2019-06-27 2020-12-30
CN110279707A (en) * 2019-07-05 2019-09-27 深圳市康宁医院(深圳市精神卫生研究所深圳市精神卫生中心) MiR-212 is preparing the application in the drug for treating habituation
US20220291233A1 (en) * 2019-07-19 2022-09-15 Universiteit Antwerpen Mucin isoforms in diseases characterized by barrier dysfunction
KR102346864B1 (en) * 2019-07-24 2022-01-04 한국전자기술연구원 Biomarker composition for diagnosing or prognostic analysis of bladder cancer, kit comprising the same and method for diagnosing bladder cancer using the same
WO2021026172A1 (en) 2019-08-05 2021-02-11 Seer, Inc. Systems and methods for sample preparation, data generation, and protein corona analysis
CN110295228A (en) * 2019-08-05 2019-10-01 中国人民解放军总医院第八医学中心 Detect application of the substance of GATA2 in preparation diagnostic activities kit lungy
CN110551809A (en) * 2019-08-21 2019-12-10 昆明医科大学第一附属医院 Application of miR-124 in spinal cord injury repair
CN110564867B (en) * 2019-10-10 2022-06-24 扬州大学 SNP molecular marker of Qinchuan cattle CFL1 gene and detection method thereof
CN110643672A (en) * 2019-10-15 2020-01-03 西安交通大学 Medical application of high-expression TrkB as novel target point in inhibiting pancreatic cancer metastasis
CN115244149B (en) * 2019-12-27 2023-09-15 关西涂料株式会社 Paint manufacturing method, color data prediction method and computer color matching system
CN111647658B (en) * 2020-06-05 2022-09-27 上海市第一人民医院 Application of LINC00963 related oncogenic axis in early diagnosis and treatment of prostate cancer distant metastasis
CN111690746A (en) * 2020-06-30 2020-09-22 镇江维思生物科技有限责任公司 Platelet RNA marker related to lung cancer and application thereof
CN113940999B (en) * 2020-07-15 2022-11-29 中国农业大学 Application of target point for treating non-alcoholic fatty liver disease
CN112180100A (en) * 2020-09-27 2021-01-05 西安交通大学 Application of TWEAK as molecular marker for identifying different types of psoriasis
CN112255408B (en) * 2020-10-16 2023-04-14 牡丹江医学院 Tumor biomarker and tumor detection kit
CN112285195B (en) * 2020-10-27 2021-08-10 江南大学 Characteristic glycoprotein marker of milk exosome and characteristic marker separation method of milk exosome
CN112433053A (en) * 2020-11-20 2021-03-02 四川大学华西医院 Application of Tetraspin-14 protein detection reagent in preparation of lung cancer screening kit
CN112301133B (en) * 2020-12-01 2021-07-27 江门市中心医院 Application of cholesterol generation gene label in prognosis prediction of young breast cancer patient
KR102427057B1 (en) * 2020-12-04 2022-07-29 전남대학교산학협력단 Biomaker for metastasis prediction or prognosis analysis of Solitary fibrous tumor/hemangiopericytoma and diagnosis method using there of
EP4269613A1 (en) 2020-12-24 2023-11-01 Pontificia Universidad Católica De Chile In-vitro method for diagnosing and predicting the aggressiveness of thyroid cancer, and the precision surgery options and type to be used to remove a tumour from a patient; kit; reagents forming the kit; and use of the reagents and use of molecular markers as part of the method
CN113151460B (en) * 2021-01-29 2022-10-18 复旦大学附属中山医院 Gene marker for identifying lung adenocarcinoma tumor cells and application thereof
CN115166245A (en) * 2021-04-04 2022-10-11 兰州大学第一医院 Application of CLU (CLU) and composition thereof in diagnosis of bile duct cancer and bile duct cancer diagnosis kit
KR102540416B1 (en) * 2021-04-09 2023-06-12 주식회사 애티스랩 Composition or kit for diagnosing cancer and method for diagnosis cancer
CN113125757B (en) * 2021-04-22 2022-10-28 石河子大学 Protein biomarker for early pregnancy diagnosis of sows and method for detecting early pregnancy of sows by using protein biomarker
CN113122544A (en) * 2021-04-25 2021-07-16 杭州广科安德生物科技有限公司 Aptamer specifically binding with TIMP1 protein and application thereof
CN113311166B (en) * 2021-04-28 2022-10-28 新疆农垦科学院 Protein biomarker for diagnosing early pregnancy of sheep and method for detecting early pregnancy of sheep
CN113186267A (en) * 2021-06-07 2021-07-30 上海康黎诊断技术有限公司 Primer-probe combination, kit and method for detecting human CYP2D6 copy number variation and genotyping
CN113687076B (en) * 2021-07-14 2024-03-01 郑州大学 Combined detection serum marker for early diagnosis of lung adenocarcinoma and application thereof
GB202111635D0 (en) * 2021-08-13 2021-09-29 Randox Laboratories Risk prediction model for prostate cancer
TWI829369B (en) * 2021-09-29 2024-01-11 日商西尾股份有限公司 beauty method
WO2023064883A1 (en) * 2021-10-14 2023-04-20 The University Of Chicago Immunotherapeutic methods for treating cancer
WO2023140658A1 (en) * 2022-01-24 2023-07-27 고려대학교 산학협력단 Pharmaceutical composition for diagnosing, preventing or treating sepsis by using brain-derived neurotrophic factor
WO2023169686A1 (en) * 2022-03-10 2023-09-14 Buzzard Pharmaceuticals AB Inhibitor of interleukin-1 receptor type 1 for use in the treatment of cancer
WO2024050856A1 (en) * 2022-09-06 2024-03-14 南京市第一医院 Method and system for assisting blood cell analyzer in determining abnormal platelet aggregation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092153A2 (en) * 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
WO2009015357A1 (en) * 2007-07-25 2009-01-29 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
US20050152908A1 (en) * 2003-11-03 2005-07-14 Genenews Inc. Liver cancer biomarkers
US20090203533A1 (en) * 2005-07-08 2009-08-13 Siemens Medicals Solutions Diagnositcs Gmbh Methods and Kits for Predicting and Monitoring Direct Response to Cancer Therapy
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2008069881A2 (en) * 2006-11-06 2008-06-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
CA2705952C (en) * 2007-11-23 2018-05-01 British Columbia Cancer Agency Branch Methods for detecting lung cancer and monitoring treatment response
US8617806B2 (en) * 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
JP2011524164A (en) * 2008-06-06 2011-09-01 サントル・ナシオナル・ドウ・ラ・ルシエルシユ・シアンテイフイク（セー・エヌ・エール・エス） Use of endolysosomal systems and secretory vesicles (exosome-like) in small RNA based therapeutics and diagnostics and experimental studies of small RNAs
JP2012507300A (en) * 2008-10-30 2012-03-29 カリス ライフ サイエンシズ ルクセンブルク ホールディングス Method for evaluating RNA patterns
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
US20130029339A1 (en) * 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
US20110166030A1 (en) * 2009-09-30 2011-07-07 Yixin Wang Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells
EP2507393A4 (en) * 2009-11-30 2013-05-01 Caris Life Sciences Luxembourg Holdings Methods and systems for isolating, storing, and analyzing vesicles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092153A2 (en) * 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
WO2009015357A1 (en) * 2007-07-25 2009-01-29 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
T. DENG ET AL: "Abstract 444: Subpopulations of circulating microvesicles have different microRNA profiles", CANCER RESEARCH, vol. 71, no. 8 Supplement, 15 April 2011 (2011-04-15), pages 444 - 444, XP055168378, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2011-444 *
TA DENG ET AL: "Subpopulations of Circulating Microvesicles Have Different MicroRNA Profiles", 7 April 2011 (2011-04-07), XP055168385, Retrieved from the Internet <URL:http://www.carislifesciences.com/media/pdf/Spetzler-sorted-MiRs-AACR-poster-2011.pdf> [retrieved on 20150209] *
TRACI PAWLOWSKI ET AL: "Circulating exosomes may provide an alternate platform to monitor disease progression compared to circulating tumor cells CD-81 Labeled Exosome Level vs CTCs in Plasma Derived Exosomes miR-21 Copy Number vs CTCs in EpCAM+ Plasma Derived Exosomes", 5 July 2010 (2010-07-05), XP055168408, Retrieved from the Internet <URL:http://www.carislifesciences.com/media/pdf/ASCO_Pawlowski2010.pdf> [retrieved on 20150209] *

Also Published As

Publication number Publication date
CN103874770A (en) 2014-06-18
WO2013022995A3 (en) 2013-04-04
AU2012294458A1 (en) 2014-02-27
WO2013022995A2 (en) 2013-02-14
JP2014522993A (en) 2014-09-08
EP2742154A2 (en) 2014-06-18
CA2844671A1 (en) 2013-02-14
BR112014002975A2 (en) 2017-03-01
KR20140067001A (en) 2014-06-03

Similar Documents

Publication Publication Date Title
HUS2100012I1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
EP2742154A4 (en) Biomarker compositions and methods
EP2721179A4 (en) Biomarker compositions and methods
EP2922861A4 (en) Biomarker compositions and methods
EP2823306A4 (en) Biomarker compositions and methods
SI2791160T1 (en) Modified mrna compositions
HK1202625A1 (en) Compositions and methods for assessing appendicitis
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
GB201408236D0 (en) Composition and method
GB201122195D0 (en) Composition and method
EP2672822A4 (en) Methods and compositions for improving cognitive function
GB201411762D0 (en) Precoating methods and compositions
EP2734646A4 (en) Compositions and methods for selecting aptamers
PL2667710T3 (en) Insescticidal composition and processes related thereto
ZA201308892B (en) Compositions and methods
EP2766357A4 (en) Meso-biliverdin compositions and methods
IL227384A0 (en) Metal-passivating cmp compositions and methods
GB201106433D0 (en) Composition and method
IL239426A0 (en) Biomarker methods and compositions
HK1203232A1 (en) Biomarker and use thereof
IL231798A0 (en) Method and composition
IL230868A0 (en) Biomarker compositions and methods
GB201116340D0 (en) Compositions and methods
GB201117620D0 (en) Method and composition
GB201116421D0 (en) Composition and method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140226

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CARIS LIFE SCIENCES SWITZERLAND HOLDINGS GMBH

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20150217BHEP

Ipc: G01N 33/68 20060101ALI20150217BHEP

Ipc: G01N 33/53 20060101ALI20150217BHEP

Ipc: G01N 33/566 20060101ALI20150217BHEP

Ipc: C12Q 1/68 20060101AFI20150217BHEP

Ipc: G01N 33/574 20060101ALI20150217BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BROWN, KIRK

Inventor name: SPETZLER, DAVID

Inventor name: PAWLOWSKI, TRACI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PAWLOWSKI, TRACI

Inventor name: BROWN, KIRK

Inventor name: SPETZLER, DAVID

A4 Supplementary search report drawn up and despatched

Effective date: 20150713

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20150707BHEP

Ipc: G01N 33/53 20060101ALI20150707BHEP

Ipc: G01N 33/574 20060101ALI20150707BHEP

Ipc: G01N 33/566 20060101ALI20150707BHEP

Ipc: C12Q 1/68 20060101AFI20150707BHEP

Ipc: G01N 33/68 20060101ALI20150707BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170516

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170927